Brad Mas, CFA, CPA

Experience

• 

  PwC

  Sept 2012 - Aug 2013

  Advisory - Deals Due Diligence

  Commonly known as the Deals department; worked with both Private Equity and Corporate clients providing M&A financial due diligenceCompleted internship program in the group (Summer 2011)

• 

  Needham & Company

  Sept 2013 - Aug 2015

  Equity Research Associate

  Worked for two Managing Director/Senior Analysts in the Equity Research department, providing analysis for both our Healthcare (Medical Technologies, Devices, and Diagnostics) and Technology (Advanced Industrial Technologies) teams

• 

  Bank of America Merrill Lynch

  Aug 2015 - Aug 2017

  Equity Research Associate

  Worked on the U.S. Medical Technology Equity Research team under Bob Hopkins, annually ranked as a Top 3 team in the sector by Institutional Investor.

• 

  Point72

  Sept 2017 - Aug 2020

  Investment Analyst

  Investment analyst covering Medical Technology/Devices and Life Science Tools/Diagnostics on a Healthcare team led by PM Richard Adams (Fundamental Equity Long/Short, market neutral)

• 

  ExodusPoint Capital Management, LP

  Aug 2020 - May 2021

  Investment Analyst

  Medical Technology/Devices analyst on a Healthcare team led by PM Paul Chung (Fundamental Equity Long/Short, market neutral)

• 

  Cinctive Capital

  May 2021 - Nov 2022

  Senior Investment Analyst

  Medical Technology/Devices analyst on a Healthcare team led by PM Paul Chung (Fundamental Equity Long/Short, market neutral). Entire team opportunistically transitioned to Cinctive together

• 

  Point72

  Nov 2022 - now

  Senior Investment Analyst

  Medical Technology/Devices Sector Head, on a Healthcare team led by PM Peter Goodwin (Fundamental Equity Long/Short, market neutral)